Financial Performance - The estimated net profit attributable to shareholders for 2023 is expected to be 18.24 million yuan, a decrease of 45.82% compared to the same period last year, which was 33.66 million yuan [3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be 14.23 million yuan, a decrease of 54.89% compared to the same period last year [4]. - The decline in net profit is attributed to intensified competition in the plant extraction industry and price reductions to maintain market share [5]. Sales and Market Trends - Sales revenue from the quercetin product line decreased by 57.67% due to weak market demand and significant price drops [5]. - The company experienced a 21.56% year-on-year increase in sales revenue in Q4 2023, indicating a gradual recovery in business operations [5]. Strategic Plans - The company plans to leverage its domestic GMP certification and food production licenses to expand into the domestic raw materials and food markets in 2024 [5]. - The company aims to optimize its product structure and enhance service capabilities to improve core competitiveness and profitability [5]. Investment Caution - The company emphasizes the importance of cautious investment decisions as the financial data for 2023 is preliminary and unaudited [6].
欧康医药(833230) - 2023 Q4 - 年度业绩预告